Review
Cell Biology
Amila Iriskic Atic, Maja Thiele, Alexander Munk, Louise Torp Dalgaard
Summary: MicroRNAs (miRNAs) secreted by the liver have the potential to be important biomarkers for nonalcoholic liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Several miRNAs, including miR-122, miR-21, miR-34a, miR-192, miR-193, and the miR-17-92 miRNA-cluster, are consistently associated with NAFLD/NASH. These miRNAs show potential as diagnostic markers for NAFLD/NASH, although more research is needed to understand their specificity and regulation.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Article
Endocrinology & Metabolism
Yuanye Jiang, Xiaoyu Zhuang, Jiaqi Zhang, Meng Li, Shengnan Du, Jiyun Tian, Yifu Yuan, Guang Ji, Cheng Hu
Summary: This study investigated the clinical and proteomic characteristics of lean individuals with NAFLD, and found that they exhibit distinct clinical profiles compared to overweight individuals with NAFLD. Plasma proteomic profiling revealed potential biomarkers with diagnostic value for lean NAFLD. These proteins are primarily involved in lipid metabolism, immune and complement systems, and platelet degranulation.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Gastroenterology & Hepatology
Sang Bong Ahn
Summary: Nonalcoholic fatty liver disease (NAFLD) affects a significant portion of the global population and includes various stages such as nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Early detection and diagnosis of liver steatosis are important in preventing the progression of severe liver diseases. This report provides an overview of currently known serum biomarkers for liver steatosis and offers guidance on their practical application in clinical settings.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Immunology
Zhenya Guo, Xiude Fan, Jianni Yao, Stephen Tomlinson, Guandou Yuan, Songqing He
Summary: This review provides an overview of the role of the complement system in nonalcoholic fatty liver disease (NAFLD), highlighting its involvement in insulin resistance, lipid metabolism disorder, and hepatic inflammation. The review aims to contribute to the development of novel therapeutic strategies for NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Endocrinology & Metabolism
Milian Chen, Ying Cao, Guang Ji, Li Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) has become a common chronic liver disease worldwide. It is commonly associated with obesity, but can also occur in lean individuals, known as lean NAFLD. Lean NAFLD is often accompanied by sarcopenia, progressive loss of muscle mass and quality. The pathological features of lean NAFLD contribute to the development of sarcopenia, while sarcopenia further exacerbates ectopic fat accumulation and lean NAFLD. In this review, we discuss the association between sarcopenia and lean NAFLD, summarize the underlying pathological mechanisms, and suggest potential strategies to reduce the risks of lean NAFLD and sarcopenia.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Gastroenterology & Hepatology
Javier Ampuero, Rocio Aller, Rocio Gallego-Duran, Javier Crespo, Javier Abad, Agueda Gonzalez-Rodriguez, Judith Gomez-Camarero, Joan Caballeria, Oreste Lo Iacono, Luis Ibanez, Javier Garcia-Samaniego, Rosa Martin-Mateos, Ruben Frances, Conrado Fernandez-Rodriguez, Moises Diago, German Soriano, Raul J. Andrade, Raquel Latorre, Francisco Jorquera, Rosa M. Morillas, Desam Escudero, Pamela Estevez, Manuel Hernandez-Guerra, Salvador Augustin, Maria Jesus Pareja-Megia, Jesus M. Banales, Patricia Aspichueta, Salvador Benlloch, Jose Miguel Rosales, Javier Salmeron, Juan Turnes, Manuel Romero-Gomez
Summary: The study investigated the distribution of NASH and its components across fibrosis stages, revealing a decrease in steatohepatitis prevalence in advanced liver disease. However, most patients still showed inflammatory activity and metabolic disturbances. The risk of cirrhosis progression was similar between NASH and indeterminate NASH patients.
LIVER INTERNATIONAL
(2021)
Review
Nutrition & Dietetics
James Westley Heinle, Kara DiJoseph, Angelo Sabag, Sechang Oh, Scot R. R. Kimball, Shelley Keating, Jonathan G. G. Stine
Summary: Exercise is a key component of NAFLD treatment, and its mechanisms involve modulating fatty acid metabolism, reducing hepatic inflammation, and improving liver fibrosis. The activation of key receptors and pathways plays a role in the degree of NAFLD-related improvements, which can be influenced by exercise type, intensity, and volume. Importantly, the therapeutic targets of exercise are also the focus of drug development studies for NASH, and exercise is likely to remain integral in the clinical management of NAFLD and NASH even with the availability of approved drugs.
Review
Immunology
Ke-qian Chen, Bo-yi Ke, Lu Cheng, Xiao-qing Yu, Zong-bao Wang, Shu-zhi Wang
Summary: With the development of the social economy, unhealthy living habits and eating styles are gradually affecting people's health in recent years. NAFLD, as a chronic liver disease, has become an increasingly serious public health problem due to these factors. Inflammasomes, as a protein complex, play a crucial role in the development of NAFLD and other diseases.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Ju Won Lee, Seung Ha Park
Summary: The study found a significant association between depression and NAFLD, with insulin resistance playing a major role in modulating this association. Adjustment for sociodemographic features and waist circumference had limited effect on the results. Further adjustment for comorbidities reduced the estimated risk of depression.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Medicine, General & Internal
Hang Gong, Huang Zhong, Hui-Mei Xu, Xiong-Chang Liu, Liang-Ping Li, De-Kui Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that increases the risk of extrahepatic diseases such as cardiovascular disease and portal vein thrombosis. NAFLD patients have an elevated risk of developing thrombosis in both the portal and systemic circulation. The increased portal pressure is a critical factor in the development of portal vein thrombosis in NAFLD patients. The underlying mechanisms of NAFLD complicated with PVT are not fully understood, and the higher risk of PVT in NAFLD is often overlooked by gastroenterologists.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Yuting Ma, Guangdong Zhang, Zenggguang Kuang, Qian Xu, Tongtong Ye, Xue Li, Na Qu, Fang Han, Chengxia Kan, Xiaodong Sun
Summary: Empagliflozin (EMPA) therapy has been shown to improve non-alcoholic fatty liver disease (NAFLD) patients. This study investigated the functional implications of EMPA on the pathogenesis of NAFLD and identified the underlying molecular mechanisms. The results showed that EMPA treatment reversed liver damage by upregulating Sestrin2 and activating the AMPK-mTOR pathway, leading to the inhibition of lipogenesis and inflammation. These findings suggest that EMPA therapy could target Sestrin2 to alleviate lipogenesis and inflammation in obesity-related NAFLD.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Food Science & Technology
Hui Han, Yi Jiang, Mengyu Wang, Mebratu Melaku, Lei Liu, Yong Zhao, Nadia Everaert, Bao Yi, Hongfu Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder that is closely related to gut dysfunction. The bidirectional communication between the gut and liver, mediated by metabolites, plays a role in the pathogenesis of NAFLD.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2023)
Article
Immunology
Jingxuan Zhou, Nanhai Zhang, Adil Aldhahrani, Mohamed Mohamed Soliman, Liebing Zhang, Feng Zhou
Summary: Puerarin improves high-fat and high-fructose diet-induced nonalcoholic fatty liver disease (NAFLD) by modulating liver lipid accumulation, liver function, oxidative stress, and inflammation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Richie Manikat, Mindie H. Nguyen
Summary: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is associated with metabolic syndrome and often presents with comorbidities such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD is also linked to non-liver comorbidities including cardiovascular disease, chronic kidney disease, and sleep apnea. Managing these comorbidities is crucial for improving liver-related and overall health outcomes in patients with NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Laia Bertran, Marta Portillo-Carrasquer, Carmen Aguilar, Jose Antonio Porras, David Riesco, Salome Martinez, Margarita Vives, Fatima Sabench, Eva Gonzalez, Daniel Del Castillo, Cristobal Richart, Teresa Auguet
Summary: The study found that circulating SFRP5 levels are influenced by diet, with hepatic SFRP5 potentially playing a protective role in the early stages of NAFLD; however, it may become dysregulated in the advanced stages of the disease while WNT5A and JNK are activated, promoting liver damage.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Terry Cheuk-Fung Yip, Eduardo Vilar-Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai-Hung Wong, Leon A. Adams, Victor de Ledinghen, Silvia Sookoian, Vincent Wai-Sun Wong
Summary: NAFLD has become a major public health problem with diverse disease burden across geographical areas and ethnicities. The associated comorbidities and complications have a significant impact on patients' quality of life, healthcare systems, and economy.
Article
Gastroenterology & Hepatology
Yusuf Yilmaz, Ahmet Eren Toraman, Ceyda Alp, Zehra Dogan, Caglayan Keklikkiran, Maria Stepanova, Zobair Younossi
Summary: Patients with more advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Several non-invasive tests (NITs) for fibrosis are associated with PROs. The PRO scores of patients with NAFLD are lower than those of matched patients with chronic hepatitis B.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Yusuf Yilmaz, Zobair Younossi
Summary: This article is related to the papers of Yilmaz et al. To access these papers, please visit the link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Arun J. Sanyal, Julie Foucquier, Zobair M. Younossi, Stephen A. Harrison, Philip N. Newsome, Wah-Kheong Chan, Yusuf Yilmaz, Victor De Ledinghen, Charlotte Costentin, Ming-Hua Zheng, Vincent Wai-Sun Wong, Magdy Elkhashab, Ryan S. Huss, Robert P. Myers, Marine Roux, Aymeric Labourdette, Marie Destro, Celine Fournier-Poizat, Veronique Miette, Laurent Sandrin, Jerome Boursier
Summary: This study aims to develop and validate two new scoring systems (Agile 4 and Agile 3+) to accurately identify cirrhosis or advanced fibrosis among individuals with non-alcoholic fatty liver disease (NAFLD) attending liver clinics. The results showed that these two novel non-invasive scores outperformed existing scoring systems in identifying cirrhosis or advanced fibrosis and reduced the need for liver biopsy.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zobair M. Younossi, Ming-Lung Yu, Yusuf Yilmaz, Khalid Aida Alswat, Maria Buti, Marlen Ivon Castellanos Fernandez, Georgios Papatheodoridis, Saeed S. Hamid, Mohamed El-Kassas, Wah Kheong Chan, Ajay K. Duseja, Stuart C. Gordon, Yuichiro Eguchi, Vasily A. Isakov, Stuart K. Roberts, Jian-Gao Fan, Ashwani K. Singal, Manuel Romero-Gomez, Aijaz Ahmed, Janus Ong, Brian P. Lam, Issah Younossi, Fatema Nader, Andrei Racila, Maria Stepanova, Saleh Alqahtani
Summary: Chronic hepatitis B (CHB) infection is a common cause of cirrhosis and liver cancer worldwide. The Global Liver Registry is being used to assess the clinical and patient-reported outcomes (PROs) of CHB patients from different regions. The study included 1818 CHB patients from 15 countries, with varying rates of advanced fibrosis. HBV subjects from the Middle East/North Africa had the lowest PRO scores, while those from Southeast/East and South Asia had the highest. Factors associated with PRO impairment in CHB patients included advanced fibrosis, non-hepatic comorbidities, and female sex.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Gastroenterology & Hepatology
Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Virend Somers, Seung Up Kim, C. Anwar A. Chahal, Vincent Wai-Sun Wong, Jingjing Cai, Michael D. Shapiro, Mohammed Eslam, Philippe Gabriel Steg, Ki-Chul Sung, Anoop Misra, Jian-Jun Li, Carlos Brotons, Yuli Huang, George V. Papatheodoridis, Aijun Sun, Yusuf Yilmaz, Wah Kheong Chan, Hui Huang, Nahum Mendez-Sanchez, Saleh A. Alqahtani, Helena Cortez-Pinto, Gregory Y. H. Lip, Robert J. de Knegt, Ponsiano Ocama, Manuel Romero-Gomez, Marat Fudim, Giada Sebastiani, Jang Won Son, John D. Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupsor-Platon, Herbert Tilg, Hasmik Ghazinyan, Jerome Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian-Gao Fan, George Boon-Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming-Hua Zheng
Summary: Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is closely linked to cardiovascular disease (CVD), but the CVD risk is often underestimated. An international panel of experts conducted a Delphi survey to establish the association between MAFLD and CVD risk, and identified potential areas for future research.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Graciela E. Castro-Narro, Helena Cortez-Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven M. Francque, Hannes Hagstrom, Terry T. -K. Huang, Dana Ivancovsky Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Veronica Miller, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C. Wendy Spearman, Emmanuel A. Tsochatzis, Luca Valenti, Marcela Villota-Rivas, Shira Zelber-Sagi, Jorn M. Schattenberg, Vincent Wai-Sun Wong, Zobair M. Younossi
Summary: This study aimed to develop a research agenda for fatty liver disease, and 28 priorities were identified to address the individual and societal harms caused by this disease. Adopting this agenda can accelerate global efforts to respond to this public health threat.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Gong Feng, Luca Valenti, Vincent Wai-Sun Wong, Yasser Mahrous Fouad, Yusuf Yilmaz, Won Kim, Giada Sebastiani, Zobair M. Younossi, Virginia Hernandez-Gea, Ming-Hua Zheng
Summary: This article discusses the importance of recompensation in the field of cirrhosis, particularly in NAFLD-related cirrhosis. It provides an up-to-date perspective on the natural history of NAFLD, emphasizing its reversible nature, and discusses the mechanisms and challenges of recompensation, as well as outlining future research directions.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz
Summary: This study retrospectively evaluated the demographic characteristics, etiologies of chronic liver disease, and FibroScan (R) parameters of patients referred to a tertiary care center between 2013 and 2021. The results showed that nonalcoholic fatty liver disease was the most common indication for referral, followed by hepatitis B and hepatitis C.
Article
Gastroenterology & Hepatology
Ayse Sakalli Kani, Ahmet Ozercan, Haluk Tarik Kani, Fatih Eren, Kemal Sayar, Yusuf Yilmaz
Summary: This study aimed to investigate the variations in chronotype, night-eating patterns, and sleep quality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and analyze their correlation with disease severity and fibrosis. The results showed that patients with non-morningness chronotype had poorer sleep quality and a higher prevalence of night-eating behavior. In addition, age and poor sleep quality significantly impacted the presence of advanced fibrosis.
Meeting Abstract
Gastroenterology & Hepatology
Zobair M. Younossi, Marlen Castellanos Fernandez, Yusuf Yilmaz, Ming-Lung Yu, Mohamed El-Kassas, Gamal Esmat, Vasily Isakov, Vincent Wong, Yuichiro Eguchi, Khalid Alswat, Nahum Mendez-Sanchez, Ajay Duseja, Maria Buti, George Papatheodoridis, Saeed S. Hamid, Jacob George, Elisabetta Bugianesi, Wah-Kheong Chan, Ashwani K. Singal, Stuart C. Gordon, Jian Gao Fan, Manuel Romero-Gomez, Stuart K. Roberts, Janus Ong, Brian P. Lam, Marcelo Kugelmas, Issah M. Younossi, Fatema Nader, Andrei Racila, Maria Stepanova, Saleh A. Alqahtani
Meeting Abstract
Gastroenterology & Hepatology
Zobair Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vasily Isakov, Marlen Ivon Castellanos Fernandez, Vincent Wai-Sun Wong, Yuichiro Eguchi, Nahum Mendez-Sanchez, Ajay Kumar Duseja, Jacob George, Elisabetta Bugianesi, Ashwani Singal, Saeed Sadiq Hamid, Jian-Gao Fan, Khalid Alswat, George Papatheodoridis, Mohamed El Kassas, Wah-Kheong Chan, Stuart C. Gordon, Manuel Romero Gomez, Stuart Roberts, Brian Lam, Issah Younossi, Andrei Racila, Linda Henry, Saleh Alqahtani, Maria Stepanova
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Zobair Younossi, Yusuf Yilmaz, Jian-Gao Fan, Vincent Wai-Sun Wong, Mohamed El Kassas, Shira Zelber-Sagi, Alina Allen, Mary Rinella, Ashwani Singal, Stuart C. Gordon, Michael Fuchs, Wayne Eskridge, Naim Alkhouri, Khalid Alswat, Hirokazu Takahashi, Takumi Kawaguchi, Jane Ranagan, Ming-Hua Zheng, Ajay Kumar Duseja, Patrizia Burra, Carrieri Patrizia, Marco Arrese, Achim Kautz, Janus Ong, Laurent Castera, Sven Francque, Marcelo Kugelmas, Yuichiro Eguchi, Sombat Treeprasertsuk, Marlen Ivon Castellanos Fernandez, Manuel Romero Gomez, Philip N. Newsome, Kenneth Cusi, Rohit Loomba, Jorn Schattenberg, Ming-Lung Yu, Moises Diago, Lynn Gerber, Brian Lam, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Saleh Alqahtani, Jeffrey Lazarus
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Ilkay Ergenc, Hasan Yapici, Caglayan Keklikkiran, Yusuf Yilmaz
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yusuf Yilmaz, Mujdat Zeybel, Gupse Adali, Arif Mansur Cosar, Elif Sertesen, Hale Gokcan, Halil Ibrahim Bahcecioglu, Mustafa Sahin, Cansin Tulunay, Ihsan Ergun, Ilker Turan, Ilkay Sedakat Idilman, Cigdem Celikel, Hale Kirimlioglu, Gulen Akyol, Funda Yilmaz, Cenk Sokmensuer, Hakan Guveli, Ulus Salih Akarca, Umit Akyuz, Volkan Genc, Murat Akyildiz, Nuray Yazihan, Engin Tutar, Fehmi Ates, Dinc Dincer, Yasemin Balaban, Murat Kiyici, Meral Akdogan, Abdullah Sonsuz, Ramazan Idilman
Summary: Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. This guidance aims to provide a standardized approach to diagnosing and treating NAFLD patients and reflects the advances in the field.
